OraSure Technologies Corporate Fact Sheet

Company Overview

OraSure Technologies develops, manufactures and markets oral fluid specimen collection devices using proprietary oral fluid technologies, diagnostic products including immunoassays and other in vitro diagnostic tests, and other medical devices. These products are sold in the United States as well as internationally to various clinical laboratories, hospitals, clinics, community-based organizations and other public health organizations, distributors, government agencies, physicians' offices, and commercial and industrial entities.

In addition, OraSure sells products for the cryosurgical removal of common and plantar warts in the over-the-counter or retail market in Mexico, certain European countries, Australia and New Zealand and a product for the cryosurgical removal of common and plantar warts and several other benign skin lesions to the professional or physician office market in the United States and many foreign countries.

OraSure Technologies is the leading supplier of oral fluid collection devices and assays to the life insurance industry and public health markets for the detection of antibodies to HIV. In addition, the Company supplies oral-fluid testing solutions for drugs of abuse testing.

Executive Team

  • Douglas A. Michels, President and Chief Executive Officer
  • Ronald H. Spair, Chief Operating Officer and Chief Financial Officer
  • Stephen R. Lee, Executive Vice President and Chief Science Officer
  • P. Michael Formica, Executive Vice President, Operations and General Manager, Cryosurgery
  • Henry B. Cohen, Senior Vice President, Human Resources
  • Jack E. Jerrett, Senior Vice President, General Counsel and Secretary
  • Mark Kirtland, Senior Vice President, Business Development
  • Debra Y. Fraser-Howze, Vice President of Government and External Affairs
  • Robert Gregg, Vice President, Regulatory Affairs
  • Ron Ticho, Vice President, Marketing and Communications

Clients

OraSure TechnologiesÕ client base includes hospitals, public health agencies, physiciansÕ offices, clinical laboratories, workplace sites, insurance companies and criminal justice facilities in the United States and abroad.

Employees

290

OraSure Technologies develops, manufactures and markets point-of-care, oral fluid specimen collection devices that leverage proprietary oral fluid technologies, diagnostic products, including immunoassays and other in vitro diagnostic tests, and other medical devices.

These products include tests for the detection of antibodies for the HIV virus, including OraQuick ADVANCE® Rapid HIV-1/2 Antibody Test and the OraSure® HIV-1 Oral Specimen Collection Device, and oral fluid testing solutions for drugs of abuse testing, including Intercept® Oral Fluid Drug Testing System and Q.E.D.® Saliva Alcohol Test. The Company also manufactures and sells several leading products for the cryosurgical removal of common and plantar warts and several other benign skin lesions.

Infectious Disease

  • OraQuick ADVANCE® Rapid HIV-1/2 Antibody Test – the first and only FDA approved, CLIA-waived, rapid point-of-care test that can detect antibodies to both HIV-1 and HIV-2 with greater than 99% accuracy in as little as 20 minutes, using an oral fluid, fingerstick or venipuncture whole blood, or plasma sample.
  • OraSure® HIV-1 Oral Specimen Collection Device – the only FDA approved, laboratory-based collection device that collects oral fluid to test for antibodies to the HIV-1 virus.

Substance Abuse

  • Intercept® Oral Fluid Drug Testing System – an FDA-cleared oral fluid drugs of abuse test that provides a smart alternative to costly, inconvenient and often embarrassing urine drug testing. This testing service detects the "NIDA-5" drug panel (marijuana, cocaine, opiates, PCP and amphetamines) plus barbiturates, methadone and benzodiazepines without the need to collect urine.
  • Q.E.D.® Saliva Alcohol Test – an FDA-cleared on-site, low-cost alternative to breath or blood testing for alcohol. The test is easy to administer and provides quantitative results as accurate as a blood test.

Cryosurgical Treatment

  • Histofreezer® Portable Cryosurgical System – an FDA-cleared, low-cost, highly effective cryosurgical system sold to physicians for the treatment of warts and a variety of other types of benign skin lesions.
  • Freeze 'n Clear Skin Clinic™ Advanced Wart Remover – an FDA-cleared, cryosurgical wart treatment product sold over-the-counter in the United States for the treatment of common and plantar warts.
  • Scholl Freeze Verruca & Wart Remover – cryosurgical wart treatment product sold over-the-counter in Europe for the treatment of common and plantar warts; manufactured by OraSure and distributed by SSL International plc under the Scholl and Dr. Scholl trademarks.
  • Pointts® Wart Remover – cryosurgical wart treatment product sold over-the-counter in Central and Latin America for the treatment of common and plantar warts; manufactured by OraSure and distributed by Genomma Lab® Internacional.

Headquarters

220 East First Street
Bethlehem, PA 18015
In the U.S.: 1-800-ORASURE
(1-800-672-7873)

Outside U.S.: (001) 610-882-1820
Fax: (001) 610-882-1825

Stock Symbol

NASDAQ: OSUR

Investor Relations

Judy Clarke
Phone: 610-882-1820
E-mail: investorinfo@orasure.com

Web Site

www.orasure.com

Media Relations

Marybeth Sheppard
Phone: 646-808-4986
E-mail: Marybeth@0to5.com

Selected Financial Information

        Six Months Ended
                June 30
                (Unaudited)
2009 2008
Revenues $ 34,530,012 $37,035,017
Net (loss) $ (6,777,653) $  (241,557)
Loss per share – Basic and Diluted $ (0.15) $ (0.01)
Number of shares – Basic and Diluted 45,854,255 46,815,277

Page last updated: October 27, 2009